Vaccine development - 02/06/2020 CureVac as a pioneer of mRNA technology - what is behind the novel COVID-19 vaccine? All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
Classification - Clinical Evidence - Evaluation - 08/07/2020 From IVDD to IVDR – smart transition (im-)possible? Online, Registration deadline: 30/06/2020https://www.bio-pro.de/en/events/past-events/ivdd-ivdr-smart-transition-im-possible-classification-clinical-evidence-evaluation
Funding Novartis announces broad range of initiatives to respond to COVID-19 Pandemic Funding programme, Funded by: Novartis AGhttps://www.gesundheitsindustrie-bw.de/en/database/funding/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic
Funding Novartis announces broad range of initiatives to respond to COVID-19 Pandemic Funding programme, Funded by: Novartis AGhttps://www.bio-pro.de/en/service/funding/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic
Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Waiting for a SARS-CoV-2 vaccine Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
Article - 22/10/2019 Using CAR T cells for treating cancer After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.https://www.gesundheitsindustrie-bw.de/en/article/news/using-car-t-cells-for-treating-cancer
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Article - 18/03/2019 EHR and PHR: digital records in the German healthcare system EHRs, i.e. electronic health records (German: Patientenakte, ePA), are hailed as the key to increasing the quality of care. The Appointment Service and Supply Act (TSVG), adopted on 14th March 2019, requires the German statutory health insurance funds to provide policyholders with electronic health records from 1st January 2021 onwards.https://www.gesundheitsindustrie-bw.de/en/article/news/ehr-and-phr-digital-records-in-the-german-healthcare-system
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Dossier - 08/03/2018 Building sustainably - actively protecting the climate Using renewable and recycled raw materials, minimising the use of water and energy during construction works and subsequent operation of a building, conserving resources and protecting the environment while maintaining biodiversity are all important components of sustainable building construction.https://www.biooekonomie-bw.de/en/articles/dossiers/building-sustainably-actively-protecting-the-climate
Dossier - 17/01/2017 Phytopharmaceuticals – fighting disease with natural substances https://www.gesundheitsindustrie-bw.de/en/article/dossier/phytopharmaceuticals-fighting-disease-with-natural-substances
Dossier - 14/06/2016 CRISPR/Cas – genome editing is becoming increasingly popular https://www.gesundheitsindustrie-bw.de/en/article/dossier/crisprcas-genome-editing-is-becoming-increasingly-popular
Dossier - 14/06/2016 CRISPR/Cas – genome editing is becoming increasingly popular https://www.biooekonomie-bw.de/en/articles/dossiers/crisprcas-genome-editing-is-becoming-increasingly-popular
The Baden-Württemberg healthcare industry The pharmaceutical industry https://www.gesundheitsindustrie-bw.de/en/location/pharma
Dossier - 10/11/2014 Cell and gene therapies from bench to bedside https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
Dossier - 04/11/2013 Biotechnology driver of innovation in the pharmaceutical industry https://www.gesundheitsindustrie-bw.de/en/article/dossier/biotechnology-driver-of-innovation-in-the-pharmaceutical-industry
Dossier - 15/10/2013 Adult stem cells hope for regenerative therapies Adult stem cells have the lifelong ability to generate new specialised cells. They secure the continuous replenishment of cells therefore enabling the constant replacement of dying cells with new ones. Progress in the characterisation isolation and specific differentiation of adult stem cells over recent years raises hopes for the future use of the cells in the therapy of degenerative diseases. Knowledge about adult stem cells also has the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/adult-stem-cells-hope-for-regenerative-therapies
Dossier - 21/05/2013 No new drugs to be placed on the market without clinical trials New pharmaceuticals are subject to approval by drug authorities. Prior to approval of a new pharmaceutical several hurdles such as preclinical and clinical studies need to be cleared. Clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/no-new-drugs-to-be-placed-on-the-market-without-clinical-trials
Dossier - 01/04/2013 Retroviruses from infectious agent to therapeutic assistant Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. Despite some similarities with accepted forms of life viruses are not considered as such. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV which leads to AIDS and for which no cure or effective vaccine is currently available. However retroviruses are not only of…https://www.gesundheitsindustrie-bw.de/en/article/dossier/retroviruses-from-infectious-agent-to-therapeutic-assistant
Dossier - 26/11/2012 Genetic diagnostics technology reaches the limits of what is medically reasonable Rapid progress in sequencing technologies is poised to set the imagination of biomedical researchers on fire. Experts now believe that progress is about to make possible what seemed to be utopian a few years ago – it seems likely that it will soon be possible to sequence the human genome in only a few minutes and store and automatically analyse it using tiny automates. However, is everything that is technically feasible also reasonable?https://www.gesundheitsindustrie-bw.de/en/article/dossier/genetic-diagnostics-technology-reaches-the-limits-of-what-is-medically-reasonable